Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal vaccine (PPV) or pneumococcal conjugate vaccine (PCV). However, there is no direct comparison study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or PPV23 in the elderly. Materials and Methods: During the 2012-2013 influenza vaccination period, 224 healthy elderly volunteers aged 65 years and older randomly received IIV3 given concomitantly with either PCV13 (PCV13+IIV3) or PPV23 (PPV23+IIV3) in a 1:1 ratio. Serum hemagglutination-inhibiting antibodies for IIV3 were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded prospectively in a clinical diary during a 7-day period. Results: A total of 220 participants blood samples for analysis of immunogenicity and kept a clinical diary for safety analysis (PCV13+IIV3, n=110; PPV23+IIV3, n=110). One month after vaccination, both groups satisfied the Committee for Medical Products for Human Use criteria for A/H1N1, A/H3N2 and B strains, showing comparable seroprotection rates, seroconversion rates and geometric mean titer fold. The assessments of immunogenicity were similar in both groups. The most common local and systemic reactions were pain at the injection site and generalized myalgia. They were generally mild or moderate in intensity. The adverse events were not statistically different between the two groups. Conclusion: PCV13+IIV3 and PPV23+IIV3 demonstrated similar immunogenicity and safety in the elderly.

Original languageEnglish
Pages (from-to)38-44
Number of pages7
JournalClinical and Experimental Vaccine Research
Volume6
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Influenza Vaccines
Vaccination
Safety
Inactivated Vaccines
Myalgia
Hemagglutination
Human Influenza
Healthy Volunteers
Pain
Injections
13-valent pneumococcal vaccine
Antibodies
Serum

Keywords

  • Immunogenicity
  • Influenza
  • Pneumococcus
  • Safety
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Immunology and Allergy
  • Pharmacology

Cite this

@article{4ab1a4d5fb2a440eb1b79d605b6e4300,
title = "Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly",
abstract = "Purpose: Previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal vaccine (PPV) or pneumococcal conjugate vaccine (PCV). However, there is no direct comparison study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or PPV23 in the elderly. Materials and Methods: During the 2012-2013 influenza vaccination period, 224 healthy elderly volunteers aged 65 years and older randomly received IIV3 given concomitantly with either PCV13 (PCV13+IIV3) or PPV23 (PPV23+IIV3) in a 1:1 ratio. Serum hemagglutination-inhibiting antibodies for IIV3 were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded prospectively in a clinical diary during a 7-day period. Results: A total of 220 participants blood samples for analysis of immunogenicity and kept a clinical diary for safety analysis (PCV13+IIV3, n=110; PPV23+IIV3, n=110). One month after vaccination, both groups satisfied the Committee for Medical Products for Human Use criteria for A/H1N1, A/H3N2 and B strains, showing comparable seroprotection rates, seroconversion rates and geometric mean titer fold. The assessments of immunogenicity were similar in both groups. The most common local and systemic reactions were pain at the injection site and generalized myalgia. They were generally mild or moderate in intensity. The adverse events were not statistically different between the two groups. Conclusion: PCV13+IIV3 and PPV23+IIV3 demonstrated similar immunogenicity and safety in the elderly.",
keywords = "Immunogenicity, Influenza, Pneumococcus, Safety, Vaccine",
author = "Seo, {Yu Bin} and Wonseok Choi and Jacob Lee and Joon-Young Song and Hee-Jin Cheong and Kim, {Woo Joo}",
year = "2017",
month = "1",
day = "1",
doi = "10.7774/cevr.2017.6.1.38",
language = "English",
volume = "6",
pages = "38--44",
journal = "Clinical and Experimental Vaccine Research",
issn = "2287-3651",
publisher = "Korean Vaccine Society",
number = "1",

}

TY - JOUR

T1 - Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly

AU - Seo, Yu Bin

AU - Choi, Wonseok

AU - Lee, Jacob

AU - Song, Joon-Young

AU - Cheong, Hee-Jin

AU - Kim, Woo Joo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: Previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal vaccine (PPV) or pneumococcal conjugate vaccine (PCV). However, there is no direct comparison study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or PPV23 in the elderly. Materials and Methods: During the 2012-2013 influenza vaccination period, 224 healthy elderly volunteers aged 65 years and older randomly received IIV3 given concomitantly with either PCV13 (PCV13+IIV3) or PPV23 (PPV23+IIV3) in a 1:1 ratio. Serum hemagglutination-inhibiting antibodies for IIV3 were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded prospectively in a clinical diary during a 7-day period. Results: A total of 220 participants blood samples for analysis of immunogenicity and kept a clinical diary for safety analysis (PCV13+IIV3, n=110; PPV23+IIV3, n=110). One month after vaccination, both groups satisfied the Committee for Medical Products for Human Use criteria for A/H1N1, A/H3N2 and B strains, showing comparable seroprotection rates, seroconversion rates and geometric mean titer fold. The assessments of immunogenicity were similar in both groups. The most common local and systemic reactions were pain at the injection site and generalized myalgia. They were generally mild or moderate in intensity. The adverse events were not statistically different between the two groups. Conclusion: PCV13+IIV3 and PPV23+IIV3 demonstrated similar immunogenicity and safety in the elderly.

AB - Purpose: Previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal vaccine (PPV) or pneumococcal conjugate vaccine (PCV). However, there is no direct comparison study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or PPV23 in the elderly. Materials and Methods: During the 2012-2013 influenza vaccination period, 224 healthy elderly volunteers aged 65 years and older randomly received IIV3 given concomitantly with either PCV13 (PCV13+IIV3) or PPV23 (PPV23+IIV3) in a 1:1 ratio. Serum hemagglutination-inhibiting antibodies for IIV3 were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded prospectively in a clinical diary during a 7-day period. Results: A total of 220 participants blood samples for analysis of immunogenicity and kept a clinical diary for safety analysis (PCV13+IIV3, n=110; PPV23+IIV3, n=110). One month after vaccination, both groups satisfied the Committee for Medical Products for Human Use criteria for A/H1N1, A/H3N2 and B strains, showing comparable seroprotection rates, seroconversion rates and geometric mean titer fold. The assessments of immunogenicity were similar in both groups. The most common local and systemic reactions were pain at the injection site and generalized myalgia. They were generally mild or moderate in intensity. The adverse events were not statistically different between the two groups. Conclusion: PCV13+IIV3 and PPV23+IIV3 demonstrated similar immunogenicity and safety in the elderly.

KW - Immunogenicity

KW - Influenza

KW - Pneumococcus

KW - Safety

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85029176464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029176464&partnerID=8YFLogxK

U2 - 10.7774/cevr.2017.6.1.38

DO - 10.7774/cevr.2017.6.1.38

M3 - Article

AN - SCOPUS:85029176464

VL - 6

SP - 38

EP - 44

JO - Clinical and Experimental Vaccine Research

JF - Clinical and Experimental Vaccine Research

SN - 2287-3651

IS - 1

ER -